nanotech-investing Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel , an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
nanotech-investing Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
nanotech-investing Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
nanotech-investing Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
nanotech-investing Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
